Two clinical-stage biotechs are potentially the next acquisition targets in biopharma, according to Wednesday afternoon reports from Bloomberg News.
T cell engager biotech Janux Therapeutics is said to be weighing a possible sale, according to one report from the news service. Meanwhile, immune drug developer Alpine…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
